Prespecified Third Interim Analysis of the DARolutamide ObservationaL (DAROL) Study

Nov 3

Written By Kristofer Prepelica, PhD

Kristofer Prepelica, PhD

PCCTC Innovation Featured at Biocom California’s “Innovations in Oncology Clinical Trial Design” Forum

The PCCTC’s Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate (TALENT) Activated